Epileptogenic potential of mefloquine chemoprophylaxis: A pathogenic hypothesis

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Nevin, Remington L ^a  

^a Camp Lemonier   (Djibouti)

Author keywords

[No Author keywords available]

Indexed keywords

MEFLOQUINE; ANTIMALARIAL AGENT;

ATAXIA; BRAIN TISSUE; CALCIUM HOMEOSTASIS; CELL DEATH; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG BRAIN LEVEL; EPILEPSY; EPILEPTOGENESIS; EPM1 GENE; FAMILY HISTORY; GAP JUNCTION; GENE; GENE MUTATION; GENOTYPE; HUMAN; HYPOTHESIS; MALARIA; MYOCLONUS; NERVE CELL; NERVE FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; NOTE; SEIZURE; TONIC CLONIC SEIZURE; TREATMENT CONTRAINDICATION; ARTICLE; CHEMICALLY INDUCED DISORDER;

ANTIMALARIALS; HUMANS; MEFLOQUINE; SEIZURES;

EID: 69849114872     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-188     Document Type: Note

References (55)

1. Mefloquine use and hospitalizations among US service members, 2002-2004. TS Wells TC Smith B Smith LZ Wang CJ Hansen RJ Reed WE Goldfinger TE Corbeil CN Spooner MAK Ryan, Am J Trop Med Hyg 2006 74 744 749 16687673
2. Prevention of malaria in long-term travelers. LH Chen ME Wilson P Schlagenhaug, JAMA 2006 296 2234 2244 10.1001/jama.296.18.2234 17090770 (Pubitemid 44708054)
3. Controversies and misconceptions in malaria chemoprophylaxis for travelers. LH Chen ME Wilson P Schlagenhauf, JAMA 2007 297 2251 2263 10.1001/jama.297.20.2251 17519415 (Pubitemid 47010883)
4. Episodic see-saw nystagmus in spino-cerebellar ataxia type 2 (SCA-2). MU Manto, Cerebellum 2002 1 91 92 10.1080/147342202753203122 12879977 (Pubitemid 44133850)
5. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. JL Bem L Kerr D Stürchler, J Trop Med Hyg 1992 95 167 179 1597872
6. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. R Steffen E Fuchs J Schildknecht U Naef M Funk P Schlagenhauf P Phillips-Howard C Nevill D Stürchler, Lancet 1993 341 1299 1303 10.1016/0140-6736(93)90814-W 8098447 (Pubitemid 23148091)
7. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. PJ Barrett PD Emmins PD Clarke DJ Bradley, BMJ 1996 313 525 528 8789977
8. Multifocal myoclonus associated with mefloquine chemoprophylaxis. A Jiménez-Huete A Gil-Nagel O Franch, Clin Neuropharmacol 2002 25 243 10.1097/00002826-200209000-00002 12410053 (Pubitemid 35239479)
9. Seizures after antimalarial medication in previously healthy persons. R Schiemann JP Coulaud O Bouchaud, J Travel Med 2000 7 155 156 11179947
10. Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. E Pous J Gascn J Obach M Corachan, Trans R Soc Trop Med Hyg 1995 89 434 10.1016/0035-9203(95)90043-8 7570889
11. Seizures after mefloquine. K Singh GD Shanks H Wilde, Ann Intern Med 1991 114 994 2024874
12. Seizure associated with mefloquine for malaria prophylaxis. TA Ruff SJ Sherwen GA Donnan, Med J Aust 1994 161 453 7935106
13. Convulsions in non-epileptics due to mefloquine-fluoroquinolone co-administration. SS Mangalvedhekar NJ Gogtay VR Wagh MS Waran D Mane NA Kshirsagar, Natl Med J India 2000 13 47 10743379
14. [Convulsions and shock during antimalarial chemoprophylaxis with mefloquine]. P Meyer N Combes P Corne O Jonquet, Presse Med 2003 32 408 12712918
15. Roche Laboratories Inc, Lariam (mefloquine hydrochloride) Complete Product Information Nutley, NJ 2008
16. Prevalence of contraindications to mefloquine among USA military personnel deployed to Afghanistan. RL Nevin PP Pietrusiak JB Caci, Malar J 2008 7 30 10.1186/1475-2875-7-30 18267019 (Pubitemid 351328663)
17. Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. DR Hill, Am J Trop Med Hyg 1991 45 263 270 1877722
18. Mefloquine-induced apoptosis in hair cells and spiral ganglion neurons in cochlear organotypic cultures. D Ding Q Weidong H Jiang R Salvi, Association for Research in Otolaryngology Meeting, 11 February 2007, Poster Session D5 http://www.aro.org/archives/2007/2007-611.html
19. Mefloquine-induced changes in apoptotic gene expression in cochlear basilar membrane and spiral ganglion neurons. H Jiang D Ding R Salvi, Association for Research in Otolaryngology Meeting, 17 February 2008, Poster Session D11 http://www.aro.org/archives/2008/2008-327-2cdaac2d.html
20. Mefloquine induces dose-related neurological effects in a rat model. G Dow R Bauman D Caridha M Cabezas F Du R Gomez-Lobo M Park K Smith, Antimicrob Agents Chemother 2006 50 1045 1053 10.1128/AAC.50.3.1045-1053.2006 16495267 (Pubitemid 43327810)
21. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. GS Dow TH Hudson M Vahey ML Koenig, Malar J 2003 2 14 10.1186/1475-2875-2-14 12848898
22. Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. GS Dow TN Heady AK Bhattacharjee D Caridha L Gerena M Gettayacamin CA Lanteri N Obaldia 3rd N Roncal T Shearer PL Smith A Tungtaeng L Wolf M Cabezas D Yourick KS Smith, Antimicrob Agents Chemother 2006 50 4132 4143 10.1128/AAC.00631-06 16966402 (Pubitemid 44865158)
23. Transcriptional profiling of mefloquine-induced disruption of calcium homeostasis in neurons in vitro. GS Dow D Caridha M Goldberg L Wolf ML Koenig DL Yourick Z Wang, Genomics 2005 86 539 550 10.1016/j.ygeno.2005.07.004 16109470 (Pubitemid 41416787)
24. Effects of mefloquine on Ca2+ uptake and release by dog brain microsomes. HS Lee ML Go, Arch Int Pharmacodyn Ther 1996 331 221 231 9124995
25. Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity. S Toovey LY Bustamante AC Uhlemann JM East S Krishna, Basic Clin Pharmacol Toxicol 2008 103 209 13 10.1111/j.1742-7843.2008.00256.x 18684232
26. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. SJ Cruikshank M Hopperstad M Younger BW Connors DC Spray M Srinivas, Proc Natl Acad Sci USA 2004 101 12364 12369 10.1073/pnas.0402044101 15297615 (Pubitemid 39145449)
27. The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro. DG Margineanu H Klitgaard, Brain Res Bull 2006 71 23 28 10.1016/j.brainresbull. 2006.07.011 17113924 (Pubitemid 44750417)
28. Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. FC Martin A Handforth, Mov Disord 2006 21 1641 1649 10.1002/mds.20940 16773639 (Pubitemid 44742192)
29. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. S Barraud de Lagerie E Comets C Gautrand C Fernandez D Auchere E Singlas F Mentre F Gimenez, Br J Pharmacol 2004 141 1214 1222 10.1038/sj.bjp.0705721 15023856 (Pubitemid 38582259)
30. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. YT Pham F Nosten R Farinotti NJ White F Gimenez, Int J Clin Pharmacol Ther 1999 37 58 61 Erratum in: Int J Clin Pharmacol Ther 1999, 37: 316 10027484
31. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. CD Riffkin R Chung DM Wall JR Zalcberg AF Cowman M Foley L Tilley, Biochem Pharmacol 1996 52 1545 1552 10.1016/S0006-2952(96) 00556-4 8937469 (Pubitemid 26375460)
32. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. E Pussard M Merzouk H Barennes, Eur J Pharm Sci 2007 32 123 127 10.1016/j.ejps.2007.06.007 17698330 (Pubitemid 47299300)
33. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. AL Aarnoudse RH van Schaik J Dieleman M Molokhia MM van Riemsdijk RJ Ligthelm D Overbosch IP van der Heiden BH Stricker, Clin Pharmacol Ther 2006 80 367 374 10.1016/j.clpt.2006.07.003 17015054 (Pubitemid 44479754)
34. Clinical pharmacokinetics of mefloquine. J Karbwang NJ White, Clin Pharmacokinet 1990 19 264 279 10.2165/00003088-199019040-00002 2208897
35. Mefloquine distribution in postmortem cases. R Jones G Kunsman B Levine M Smith C Stahl, For Sci Int 1994 68 29 32
36. Neuropsychiatric events during prophylactic use of mefloquine before travelling. MM van Riemsdijk JM Ditters MC Sturkenboom JH Tulen RJ Ligthelm D Overbosch BH Stricker, Eur J Clin Pharmacol 2002 58 441 445 10.1007/s00228-002- 0492-z 12242605
37. Glial connexins and gap junctions in CNS inflammation and disease. T Kielian, J Neurochemistry 2008 106 1000 1016 10.1111/j.1471-4159.2008.05405.x
38. Immunogold evidence that neuronal gap junctions in adult rat brain and spinal cord contain connexin-36 but not connexin-32 or connexin-43. JE Rash WA Staines T Yasumura D Patel CS Furman GL Stelmack JI Nagy, Proc Natl Acad Sci USA 2000 97 7573 7578 10.1073/pnas.97.13.7573 10861019 (Pubitemid 30431505)
39. Neuronal coupling via connexin36 contributes to spontaneous synaptic currents of striatal medium-sized spiny neurons. DM Cummings I Yamazaki C Cepeda DL Paul MS Levine, J Neurosci Res 2008 86 2147 2158 10.1002/jnr.21674 18381762
40. Connexin-36 gap junctions mediate electrical coupling between ventral tegmental area GABA neurons. DW Allison AJ Ohran SH Stobbs M Mameli CF Valenzuela SN Sudweeks AP Ray SJ Henriksen SC Steffensen, Synapse 2006 60 20 31 10.1002/syn.20272 16575850 (Pubitemid 43742954)
41. Fundamental role of inferior olive connexin 36 in muscle coherence during tremor. DG Placantonakis AA Bukovsky XH Zeng HP Kiem JP Welsh, Proc Natl Acad Sci USA 2004 101 7164 7169 10.1073/pnas.0400322101 15103021 (Pubitemid 38596460)
42. Molecular targets for antiepileptic drug development. BS Meldrum MA Rogawski, Neurotherapeutics 2007 4 18 61 10.1016/j.nurt.2006.11.010 17199015 (Pubitemid 46107329)
43. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. P Beck A Odle T Wallace-Huitt RD Skinner E Garcia-Rill, Sleep 2008 31 1647 1654 19090320
44. Clinical picture of EPM1-Unverricht-Lundborg disease. R Kälviäinen J Khyuppenen P Koskenkorva K Eriksson R Vanninen E Mervaala, Epilepsia 2008 49 549 556 10.1111/j.1528-1167.2008.01546.x 18325013 (Pubitemid 351661066)
45. Molecular background of EPM1-Unverricht-Lundborg disease. T Joensuu AE Lehesjoki O Kopra, Epilepsia 2008 49 557 563 10.1111/j.1528-1167.2007.01422.x 18028412 (Pubitemid 351661041)
46. Cystatins. M Abrahamson M Alvarez-Fernandez CM Nathanson, Biochem Soc Symp 2003 179 199 14587292
47. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. LA Pennacchio DM Bouley KM Higgins MP Scott JL Noebels RM Myers, Nat Genet 1998 20 251 258 10.1038/3059 9806543 (Pubitemid 28507669)
48. Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. K Lieuallen LA Pennacchio M Park RM Myers GG Lennon, Hum Mol Genet 2001 10 1867 1871 10.1093/hmg/10.18.1867 11555622
49. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. P Shannon LA Pennacchio MK Houseweart BA Minassian RM Myers, J Neuropathol Exp Neurol 2002 61 1085 1091 12484571
50. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. S Franceschetti G Sancini A Buzzi S Zucchini B Paradiso G Magnaghi C Frassoni M Chikhladze G Avanzini M Simonato, Neurobiol Dis 2007 25 675 685 10.1016/j.nbd.2006.11.006 17188503 (Pubitemid 46304252)
51. Seizures, ataxia, and neuronal loss in cystatin B heterozygous mice. A Kaasik M Kuum A Aonurum A Kalda A Vaarmann A Zharkovsky, Epilepsia 2007 48 752 757 10.1111/j.1528-1167.2007.00985.x 17319918 (Pubitemid 46587624)
52. Alterations in metabolism and gap junction expression may determine the role of astrocytes as "good samaritans" or executioners. R Farahani MH Pina-Benabou A Kyrozis A Siddiq PC Barradas FC Chiu LA Cavalcante JC Lai PK Stanton R Rozental, Glia 2005 50 351 361 10.1002/glia.20213 15846800 (Pubitemid 40789963)
53. Gamma-aminobutyric acid and mefloquine-induced seizures in mice. GJ Amabeoku CC Farmer, Prog Neuropsychopharmacol Biol Psychiatry 2005 29 917 921 10.1016/j.pnpbp.2005.04.030 16009480 (Pubitemid 41080112)
54. Department of the Army Office of the Surgeon General. Memorandum. Subject: Updated Guidance on Use of Mefloquine (Lariam) for Malaria Prophylaxis, 2 February 2009. http://www.pdhealth.mil/downloads/DASG-Memorandum.pdf
55. Mefloquine neurotoxicity: A literature review. S Toovey, Travel Med Infect Dis 2009 7 2 6 10.1016/j.tmaid.2008.12.004 19174293